Microbix Biosystems Inc. (TSX:MBX)
Canada · Delayed Price · Currency is CAD | Market Cap | 33.06M -32.9% |
| Revenue (ttm) | 14.81M -34.8% |
| Net Income | -5.72M |
| EPS | -0.04 |
| Shares Out | 137.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,259 |
| Average Volume | 64,279 |
| Open | 0.2300 |
| Previous Close | 0.2250 |
| Day's Range | 0.2300 - 0.2400 |
| 52-Week Range | 0.2100 - 0.3550 |
| Beta | 0.54 |
| RSI | 48.48 |
| Earnings Date | May 14, 2026 |
About Microbix Biosystems
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and... [Read more]
Financial Performance
Financial StatementsNews
Microbix Biosystems reports Q2 EPS (C$0.01) vs. C$0.00 last year
Reports Q2 revenue C$3.38M vs. C$5.32M last year. The company said, “Results for Q2 and H1 demonstrated early results of the Company’s continuing work to rebuild revenues back to profitability…
Microbix Biosystems says ‘agressively pursuing’ new client programs
The company said, “Microbix is aggressively pursuing new client programs and new clients, while continuing to add to its portfolio of products and services, and its capabilities. It thereby intends…
Microbix Biosystems Earnings Call Transcript: Q2 2026
Q2 saw revenues fall below breakeven due to a sharp drop in Chinese sales and delayed antigen orders, but non-China business grew and cost controls remain strong. QAPs revenues are expected to rebound, and Kinlytic's launch is on track for 2028, with a solid cash position supporting ongoing investments.
Microbix Biosystems Earnings release: Q2 2026
Microbix Biosystems released its Q2 2026 earnings on May 14, 2026, summarizing the period's financial results.
Microbix Reports Results for H1 & Q2 2026
H1 Revenues of $7.6 million and Controlled Net Loss MISSISSAUGA, ON / ACCESS Newswire / May 14, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF)(Microbix®), a life sciences innovator, manufactur...
Microbix Schedules Release of Results for Q2 Fiscal 2026
Results Release and Webinar Discussion on Morning of May 14, 2026 MISSISSAUGA, ON / ACCESS Newswire / May 7, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovato...
Microbix Biosystems says client presenting product results at 2026 PASCV
Microbix Biosystems (MBXBF) announces that one of its clients is presenting results of Microbix made quality assessment products that help enable full-process quality management of molecular assays to...
Microbix Product Results Being Presented at 2026 PASCV
MISSISSAUGA, ON / ACCESS Newswire / April 27, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that one of its client...
Microbix Biosystems releases episodes of ‘Diagnostics: Beyond the Lab’ podcast
Microbix Biosystems (MBXBF) is releasing three episodes of the second season of its podcast titled “Diagnostics: Beyond the Lab.” This Microbix podcast series engages with third-party experts to discu...
Microbix Engages with Diagnostics Industry Experts
Releasing Episodes of Season Two of "Diagnostics: Beyond the Lab" Podcast MISSISSAUGA, ON / ACCESS Newswire / April 20, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life scien...
Microbix Presenting at the 2026 Bloom Burton Conference
MISSISSAUGA, ON / ACCESS Newswire / April 16, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces it will be attending ...
Microbix Biosystems presenting results of QAP at ESCMID Global 2026
Microbix Biosystems (MBXBF) will be exhibiting at ESCMID Global 2026 and presenting results of a novel quality assessment product to enable full-process quality management of molecular assays to detec...
Microbix Exhibiting & Presenting at ESCMID Global 2026
Presenting Results of Novel Product for Quality Control of RNA-based Assays MISSISSAUGA, ON / ACCESS Newswire / April 15, 2026 / Microbix Biosystems Inc. (TSX: MBX)(OTCQX:MBXBF, Microbix®), a life sc...
Microbix Biosystems announces annual meeting voting results
Microbix Biosystems (MBXBF) announces the voting results from the Annual Meeting of Shareholders of the Company which was held on March 25. At the Meeting, 27.44% of the issued and…
Microbix Announces Annual Meeting Voting Results
MISSISSAUGA, ON / ACCESS Newswire / March 26, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQB:MBXBF) ("Microbix® " or the Company"), a life sciences innovator, manufacturer, and exporter, announces th...
Microbix Biosystems presents results of QUANTDx reference materials
Microbix Biosystems (MBXBF) is presenting results of novel QUANTDx reference materials designed to emulate real-life human papillomavirus patient-samples and thereby better support the validation of m...
Microbix Presents Reference-Material Innovations at EUROGIN
QUANTDx Samples with "Normalized" Viral Loads for Validating HPV Assays MISSISSAUGA, ON / ACCESS Newswire / March 17, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF)(Microbix®), a life science...
Microbix Biosystems announces advancement of clot-buster drug project
Microbix Biosystems (MBXBF) announces that the contract development and manufacturing organization engaged by its funding and commercialization partner, Sequel Pharma, has modernized production method...
Microbix's Clot-Buster Drug Project Advances
Drug Substance Manufacturing Methods Modernized MISSISSAUGA, ON / ACCESS Newswire / March 10, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacture...
Microbix Biosystems announces issuance of stock options
In consultation with management, Microbix’s Board of Directors has approved the issuance of 2,600,000 options in accordance with the terms of the Stock Option Plan. The approved options are exercisabl...
Microbix Announces Issuance of Stock Options
Using Shareholder-Approved Plan to Incentivize and Retain MISSISSAUGA, ON / ACCESS Newswire / February 24, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF) (Microbix®), a life sciences innovator...
Microbix Biosystems Earnings Call Transcript: Q1 2026
Q1 2026 revenue rebounded 13% sequentially to CAD 4.2 million, with net loss managed by cash reserves. Growth in QAPs and new client wins offset ongoing weakness in China, while annual revenue is targeted at CAD 18.5–19 million. NCIB share buybacks continue at 15,000 shares per day.
Microbix Biosystems Earnings release: Q1 2026
Microbix Biosystems released its Q1 2026 earnings on February 12, 2026, summarizing the period's financial results.
Microbix Biosystems reports Q1 revenue C$4.22M vs. C$6.04M last year
The company said, “Results for Q1 demonstrated the Company’s efforts to rebuild revenues back above its breakeven point following two client setbacks in mid-2025, with revenue growth of 13% compared…
Microbix Biosystems says ‘agressively pursuing’ new client programs
The company said, “Microbix is aggressively pursuing new client programs and new clients, while continuing to add to its portfolio of products and services, and its capabilities. It thereby intends…